Access Vascular, a company addressing the most common and costly vascular access complications with its advanced biomaterial platform, today announced that it raised a Series C round worth $22 million from a consortium of new and existing investors.

Access Vascular was founded to address the most common and costly complications of intravenous therapy: infection, thrombosis, and phlebitis. Taking a foundationally different approach to thrombus reduction, the company manufactures intravenous catheters from a proprietary hydrophilic material. Engineered to mimic the body's natural chemistry, Access Vascular catheters are designed to evade the foreign body response and the complications that come with it.